Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, December 24 through Wednesday, December 26 inclusive. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 07.12.16 in Vol 5, No 4 (2016): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.6559):

(note that this is only a small subset of citations)

  1. Megías-Vericat J, Bonanad S, Haya S, Cid A, Marqués M, Monte E, Pérez-Alenda S, Bosch P, Querol F, Poveda J. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. Thrombosis Research 2019;174:151
    CrossRef
  2. Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C. Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology 2019;12(sup1):1
    CrossRef
  3. Dargaud Y, Delavenne X, Hart D, Meunier S, Mismetti P. Individualized PK-based prophylaxis in severe haemophilia. Haemophilia 2018;24:3
    CrossRef
  4. Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2018;16(7):1437
    CrossRef
  5. Hecht M, Veigure R, Couchman L, S Barker CI, Standing JF, Takkis K, Evard H, Johnston A, Herodes K, Leito I, Kipper K. Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. Bioanalysis 2018;10(15):1229
    CrossRef
  6. Berntorp E. Replacement therapy during surgery in von Willebrand disease needs personalization. Haemophilia 2018;24(3):338
    CrossRef
  7. McEneny-King A, Chelle P, Iorio A, Edginton A. The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research 2018;170:53
    CrossRef
  8. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton A. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics 2017;9(4):47
    CrossRef
  9. Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017;23(3):e170
    CrossRef
  10. Berntorp E. If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. Journal of Thrombosis and Haemostasis 2017;15(6):1103
    CrossRef
  11. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis 2017;117(06):1023
    CrossRef
  12. Iorio A, McEneny-King A, Keepanasseril A, Foster G, Edginton A. What is the role for population pharmacokinetics in hemophilia?. International Journal of Pharmacokinetics 2017;2(2):125
    CrossRef
  13. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2017;15(12):2461
    CrossRef